Retinopathy associated with high-dose interferon alfa-2b therapy

American Journal of Ophthalmology

Volumn 131, Issue 6, 2001, Pages 782-787

  Hejny, Charles ^a   Sternberg Jr , Paul ^a   Lawson, David H ^a   Greiner, Kristen ^a   Aaberg, Thomas M ^a  

^a EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GANGLIOSIDE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VACCINE;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; BRAIN RADIATION; CANCER RISK; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPERTENSION; MELANOMA; MORBIDITY; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA NEOVASCULARIZATION; RETINOPATHY; RISK FACTOR; THROMBOCYTOPENIA; VISUAL ACUITY; VISUAL IMPAIRMENT;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; PAROXETINE; RETINAL DISEASES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; VISION DISORDERS;

EID: 0035008169     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(01)00836-4     Document Type: Article

References (16)

1. Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998;82:323-325.
2. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-alfa. Semin Oncol 1998;25(suppl 1):3-8.
3. Guyer D, Tiedeman J, Yannuzzi L, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:50-56.
4. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997;115:865-872.
5. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1995;91:309-313.
6. Chambers RB, Downie A, Foote B, Davidorf FH. Interferon alfa-associated retinopathy. J Am Osteopath Assoc 1997;97:43-45.
7. Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjuctival hemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995;79:150-152.
8. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST. J Clin Oncol 1996;14:7-17.
9. Lopez PF, Sternberg P Jr, Dabbs CK, et al. Bone marrow transplant retinopathy. Am J Ophthalmol 1991;112:635-646.
10. Physician's desk reference. Volume 53. Montvale, NJ: Medical Economics, 1999:3078-3083.
11. Lawrence KM, Falkowski J, Jacobson RR, Horton RW. Platelet 5-HT uptake sited in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine. Psychopharmacology 1993;110:235-239.
12. Helmeste DM, Tang SW, Reist C, Vu R. Serotonin uptake inhibitors modulate intracellular Ca 2+ mobilization in platelets. Eur J Pharmacol 1995;288:373-377.
13. Sugano S, Yanagimoto M, Suzuki T, et al. Retinal complications with elevated circulating plasma C5a associated with interferon-alfa therapy for chronic active hepatitis C. Am J Gastroenterol 1994;89:2054-2056.
14. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995;113:1041-1044.
15. Nao-I N, Futami H, Chuman T, et al. Prospective study of the incidence of interferon-induced retinopathy in patients with chronic hepatitis. Ophthalmology 1994; 101 (suppl): 119.
16. Chan CK, Kempin SJ, Noble SK, Palmer GA. The treatment of choroidal neovascular membranes by alpha interferon. Ophthalmology 1994;101:289-300.